Search

Displaying results 7291 - 7300 of 10000 in total
  1. Drug

    Petesicatib

    go.drugbank.com/drugs/DB15297
    Investigational

    Petesicatib is under investigation in clinical trial NCT02295332 (A Study of RG7625 in Healthy Volunteers).

  2. Drug

    Elraglusib

    go.drugbank.com/drugs/DB16047
    Investigational

    Elraglusib is under investigation in clinical trial NCT04218071 (Actuate 1901: 9-ING-41 in Myelofibrosis).

  3. Drug

    Amdizalisib

    go.drugbank.com/drugs/DB21514
    Investigational

    Amdizalisib is under investigation in clinical trial NCT05713110 (A Study of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory Lymphoma).

  4. Drug

    Maropitant

    go.drugbank.com/drugs/DB11427
    ExperimentalVet approved

    It was approved by the FDA in 2007 for use in dogs, and more recently has also been approved for use in cats. … Maropitant, used as maropitant citrate, is a neurokinin receptor antagonist, which was developed by Zoetis specifically for the treatment of motion sickness and vomiting in dogs.

  5. Drug

    Cannabivarin

    go.drugbank.com/drugs/DB14736
    Experimental

    A natural product found in Cannabis sativa.

  6. Drug

    R3R01

    go.drugbank.com/drugs/DB18078
    Investigational

    R3R01 is an investigational lipid-modifying drug.

  7. Drug

    Fasudil

    go.drugbank.com/drugs/DB08162
    Investigational

    Fasudil has been investigated in Carotid Stenosis.

  8. Drug

    CIGB 2020 Vaccine

    go.drugbank.com/drugs/DB15808
    Experimental

    The vaccine was developed and tested by the Center for Genetic Engineering and Biotechnology (CIGB), in Havana Cuba. … CIGB 2020 is a vaccine candidate administered nasally and sublingually, working to strengthen immunity in the areas administered.

  9. Drug

    BNT162a1 SARS-CoV-2 Vaccine

    go.drugbank.com/drugs/DB15697
    Experimental

    [L15002, L15007] BNT162a1 is undergoing evaluation in clinical trials in both the USA (NCT04368728) and Germany (NCT04380701).[L15017, L15022] … [L15002, L15007] BNT162a1 is a uridine mRNA (uRNA) vaccine formulated in lipid nanoparticles for delivery via intramuscular injection.

  10. Drug

    BNT162c2 SARS-CoV-2 Vaccine

    go.drugbank.com/drugs/DB15698
    Experimental

    [L15002, L15007] BNT162c2 is undergoing evaluation in clinical trials in both the USA (NCT04368728) and Germany (NCT04380701).[L15017, L15022] … [L15002, L15007] BNT162c2 is a self-amplifying mRNA (saRNA) vaccine formulated in lipid nanoparticles for delivery via intramuscular injection.